Brought to you by 
NeuCyte licenses Trillium's epilepsy candidate
27 Sep 2019
Executive Summary
NeuCyte Inc. licensed exclusive worldwide development and commercialization rights to Trillium Therapeutics Inc.'s undisclosed refractory epilepsy compound for Dravet syndrome and related disorders.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeuCyte licenses Trillium's epilepsy candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice